Selected article for: "gender age and study outcome"
Title: RESEARCH COMMUNICATIONS OF THE 28th ECVIM-CA CONGRESS
  • Document date: 2018_12_19
    • ID: r79h9yzz_851
    Snippet: In this retrospective study, treatment outcome of 107 hyperthyroid cats was evaluated. Cats were either treated with the oral anti‐thyroid drug Methimazole (Felimazole®, n=61), Carbimazole retard (Vidalta®, n=25), or Carbimazole licensed for the use in humans (CHM, n=21). Data concerning signalement (age, gender, breed), concurrent disease, number of dose adjustments, time period until an euthyroid state was reached, occurrence of adverse eff.....
    Document: In this retrospective study, treatment outcome of 107 hyperthyroid cats was evaluated. Cats were either treated with the oral anti‐thyroid drug Methimazole (Felimazole®, n=61), Carbimazole retard (Vidalta®, n=25), or Carbimazole licensed for the use in humans (CHM, n=21). Data concerning signalement (age, gender, breed), concurrent disease, number of dose adjustments, time period until an euthyroid state was reached, occurrence of adverse effects, survival time, and cause of death were evaluated in all cats and compared between treatment groups.

    Search related documents:
    Co phrase search for related documents
    • adverse effect and dose adjustment: 1
    • adverse effect and gender age: 1, 2, 3, 4, 5, 6
    • adverse effect and retrospective study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • adverse effect and survival time: 1, 2, 3
    • adverse effect and time period: 1, 2, 3, 4
    • adverse effect and treatment group: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • adverse effect and treatment outcome: 1, 2, 3
    • adverse effect occurrence and retrospective study: 1
    • adverse effect occurrence and survival time: 1
    • cat evaluate and retrospective study: 1